Trial Profile
A Study on the Effects of Chronotherapy of Hypertension with Olmesartan on Blood-pressure Variability, Sympathetic Function, and Renal Function in Patients with Type 2 Diabetes Mellitus and Hypertension
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2017
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Diabetic nephropathies; Essential hypertension
- Focus Biomarker; Therapeutic Use
- Acronyms J-CORRECT
- 06 Apr 2017 Status changed from recruiting to discontinued.
- 04 May 2013 New trial record
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.